News articles about Trevena (NASDAQ:TRVN) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trevena earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.2465670265919 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Shares in the Spotlight: Trevena Inc (TRVN) – Berry Recorder – Berry Recorder (berryrecorder.com)
- Trevena, Inc. (TRVN) is at $2.39 per share and Sierra Oncology, Inc. (SRRA) is listed at $1.52 – Stocks Gallery (stocksgallery.com)
- Most recent Trading report:: Government Properties Income Trust (GOV) (expressnewsline.com)
- Trevena Inc (TRVN) and iShares Core S&P US Value ETF (IUSV) Seeing Needle Moving This Session – Sparta Review (spartareview.com)
Several brokerages have issued reports on TRVN. Roth Capital set a $9.00 price target on shares of Trevena and gave the company a “buy” rating in a research note on Saturday, May 6th. Cowen and Company reiterated a “buy” rating and issued a $10.00 price target on shares of Trevena in a research note on Friday, August 4th. Zacks Investment Research upgraded shares of Trevena from a “sell” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Wednesday, August 9th. Oppenheimer Holdings, Inc. set a $8.00 price objective on shares of Trevena and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $9.00 price objective (down from $11.00) on shares of Trevena in a research note on Friday, May 5th. One research analyst has rated the stock with a sell rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $10.56.
Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35). Analysts forecast that Trevena will post ($1.40) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Trevena (TRVN) Stock Price” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/08/19/trevena-trvn-given-daily-media-impact-rating-of-0-07-updated.html.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
What are top analysts saying about Trevena Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trevena Inc. and related companies.